While Lilly’s clinical results pushed its shares up 1.6% following the conference, competitors including Novo Nordisk, Roche, and Pfizer saw their stock prices slide. Analysts suggest the market is shifting toward a more segmented approach, where pharmaceutical firms must balance aggressive weight-loss metrics against the significant challenge of patient tolerability. Many of the current GLP-1 treatments continue to be hampered by gastrointestinal side effects, with some drugs reporting nausea rates near 40%.

Industry players are now pivoting to differentiate their portfolios. Roche is investigating dual-acting therapies like enicepatide, while others, including AstraZeneca, are exploring oral delivery methods and combination therapies. Despite these efforts, RBC analyst Trung Huynh noted that the bar for efficacy is rising, leaving companies struggling to match Lilly’s next-generation performance. As the race intensifies, the primary battleground has shifted from raw weight reduction to creating treatments that patients can sustain long-term without debilitating side effects.